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ABSTRACT 
Background: Poor response of the ovaries to gonadotropin stimulation is associated with poor outcome 
following in vitro fertilization. The historical lack of a standard definition for poor ovarian response has resulted 
in a wide variation in prevalence and outcome measures. More recently, the Bologna criteria has emerged 
as the standard for identification of poor ovarian responders. There is paucity of literature on poor ovarian 
response in the African setting.  This study was conducted to document the prevalence and the outcome of 
in vitro fertilization among poor ovarian responders in women undergoing assisted reproduction technology 
in the public sector of Western Cape Province of South Africa. 
Method: Retrospective review of data of women who underwent assisted reproduction technology between 
January 2011 and December 2015 was conducted. The Bologna criteria was used to identify women for 
inclusion into the study. For the analysis of prevalence and treatment outcomes, only a woman’s first cycle 
at the Groote Schuur Hospital was included, however the occurrence of further cycles was recorded.   
Main results: A total of 40 women met the criteria for poor ovarian response in this study. The prevalence 
of poor ovarian response was 3.6%. The mean age among the study population was 37.8years (25 – 42yrs). 
Cycle cancellation rate due to poor ovarian response was 15.0% and the average number of eggs retrieved 
was 1.8. Twenty-four (60%) women had at least one embryo transferred. The clinical pregnancy and live birth 
rates were 10.0% and 5.0% respectively, per cycle initiated. Half of those with failed IVF due to poor ovarian 
response withdrew from the program. 
Conclusion: The prevalence of poor ovarian response among women who underwent assisted reproduction 
at Groote Schuur Hospital was 3.6% which is low compared to 9-24% reported in other studies. The clinical 
pregnancy and live birth rates were low. Half of the women did not continue with treatment after their first 
failed IVF cycle. 
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CHAPTER ONE 
1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 BACKGROUND 
The high fertility rate in Africa has created the erroneous impression that infertility is not a problem in Africa. 
On the contrary, there is high prevalence of infertility in Africa with one out of ten couples experiencing 
infertility at some point in their life(1). Moreover, the consequences of infertility in Africa are arguably more 
far reaching than those from other parts of the world. Dyer et al evaluated the psychological impact of infertility 
among women in urban South Africa and found a higher incidence of verbal and physical abuse as well as 
depression in infertile women when compared to fertile women(2). Additionally, these women experienced 
loss of social status, marital instability and poverty(3). There is therefore an immense pressure on infertile 
couples, particularly the women, to have children. In the majority of these cases, damage to the fallopian 
tubes (1, 4, 5) and male factor (4) were the reasons for the infertility. Assisted Reproductive Technology 
(ART) is therefore the only option to achieve pregnancy and their desire to have children. 
Assisted reproductive technology (ART) involves the handling or manipulation of the human oocyte and 
sperm outside the human body followed by replacement of the resultant embryo back into the uterine cavity. 
Assisted Reproductive Technology (ART) has been defined as ‘all interventions that include the in-vitro 
handling of both human oocytes and sperms, or of embryo, for the purposes of reproduction. This includes, 
but not limited to IVF (in-vitro fertilization), embryo transfer,  ICSI (intracytoplasmic sperm injection), embryo 
biopsy, PGT (preimplantation genetic testing), assisted hatching, GIFT (gamete intrafallopian transfer), 
zygote intrafallopian transfer, gamete and embryo cryopreservation, semen, oocyte and embryo donation, 
and gestational carrier cycles’ (6).   
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In-vitro fertilization comprises a sequence of procedures that involves the fertilization of the oocyte with the 
sperm outside of the human body and include conventional in-vitro fertilization (IVF), where both the oocyte, 
and the sperm are incubated in the same medium for sperms to move into and fertilize the oocyte as well as 
intra cytoplastic sperm injection (ICSI) in which case a single sperm is injected directly into the oocyte to 
initiate the process of fertilization(6). It is desirable to have an adequate number of oocytes for fertilization 
from which a good quality embryo can be selected to transfer into the uterus. In order to achieve multiple 
oocytes, the ovaries are stimulated with gonadotropin injections. 
This process of using gonadotropins to stimulate multiple oocyte development from the ovaries is referred to 
as ovarian stimulation. The aim of the ovarian stimulation is to achieve the development of multiple follicles 
containing oocytes. The main reason for poor follicular recruitment and growth and consequently not 
retrieving an adequate number of oocytes during controlled ovarian stimulation is the inability of the ovaries 
to respond satisfactorily to the gonadotropin injections(7). The concept of poor ovarian response describes 
this phenomenon. 
A poor ovarian response is the situation where only few eggs are produced when the ovaries are stimulated 
with the standard dose of gonadotropins (7). Garcia et al were the first to describe the poor ovarian responder. 
Since then several criteria have been used to define poor ovarian response(8). These criteria include number 
of dominant follicles, the number of oocytes retrieved, peak oestradiol levels, basal FSH (Follicle Stimulating 
Hormone), duration of stimulation, total amount or daily dose of FSH(9-11).These tests assess the ovarian 
reserve as a proxy to ovarian response. 
14 
The concept of ovarian reserve relates a woman's reproductive potential to the number and quality of the 
remaining oocytes in her ovaries (12). It gives an idea about the likely outcome of the ovarian response when 
stimulated with a gonadotropin. However, its use to predict the likelihood of a successful pregnancy is not 
reliable(13). The ovarian reserve screening tests commonly used in clinical practice include basal follicle 
stimulating hormone (FSH), antiműllerian hormone (AMH) levels and antral follicle count (AFC)(14, 15). The 
ovarian reserve tests used at the Groote Schuur Hospital were AMH and AFC. These two ovarian reserve 
tests were found to be the most reliable and correlate well with each other in predicting response to ovarian 
stimulation and defining poor ovarian response(16, 17). In addition to these tests, a woman’s age is an 
important clinical factor that determines ovarian response and outcome of IVF(17, 18). This presupposes that 
where there is a high proportion of older women in a population wishing to undergo infertility treatment, a 
high prevalence of poor ovarian response would be expected.  
The prevalence of poor ovarian response has been estimated to vary between 9 and 26% (19). The wide 
variation in the prevalence of poor ovarian response is the consequence of various authors using different 
definitions for poor ovarian response. In an attempt by the scientific community to standardize the definition 
of poor ovarian response in a reproducible manner, the European Society for Human Reproduction and 
Embryology (ESHRE) developed the Bologna criteria in 2011 (7). 
The Bologna criteria comprise three components (i) advanced maternal age (≥40 years old) or any other risk 
factors of poor ovarian response, (ii) previous cycle cancellation due to poor ovarian response and (iii) 
abnormal ovarian reserve test. Any two out of the three criteria is used to make the diagnosis of poor ovarian 
response(7). There has been some criticism of the Bologna criteria as the different combinations of two out 
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of the three criteria creates different subgroups rather than one identifiable group of poor ovarian responders 
(20). 
The pregnancy rate in women with poor ovarian response is generally lower compared to women with normal 
ovarian response(21, 22). Hence the majority of women with poor ovarian response may not achieve 
pregnancy in their first IVF cycle. 
The management of women with poor ovarian response often presents a challenge to the fertility specialist 
because there is no clear evidence on how to improve outcome. Some authors found a beneficial effect of 
the use of adjuvant therapies such as growth hormones, androgens and Luteinizing hormone 
supplementation during ovarian stimulation(23-25). However these therapies have not been found in 
randomized controlled trials to be effective (26). 
Once undergoing an IVF cycle, the possible options for women with poor ovarian response who wish to 
conceive include the following: 
• Cancellation of the cycle and repeating the ovarian stimulation with a higher dosage of FSH       
with the hope of achieving an adequate response (21). 
• Proceeding to follicle aspiration and using the limited number of oocytes available(21) 
• .. Repeat IVF cycle using donor Eggs  (27) 
There is also the option of curtailing the ART program and adopting a child, thus  making the couple legal 
and social parents (28). 





1.2 LITERATURE REVIEW 
As part of this study, a literature review was conducted. The review focused on issues relating to the definition 
and prevalence of poor ovarian response, the identification of poor ovarian responders, gonadotropin dose 
for ovarian stimulation, cycle cancelation and the number of eggs retrieved. The literature on the outcomes 
of pregnancies in poor ovarian responders and the decisions that couple made after an IVF failure were also 
reviewed. 
 
1.3  DEFINITION OF POOR OVARIAN RESPONSE 
Some women produce few eggs when their ovaries are stimulated with the standard doses of gonadotropins 
during ovarian stimulation for IVF. These women are referred to as poor ovarian responders. The population 
of women who are poor ovarian responders are not a homogenous group but a subpopulation with various 
characteristics (7). It is therefore not an easy task to define or identify a poor ovarian responder. 
The poor ovarian responder has been defined differently by different authors. In a notable systematic review, 
Polyzos and Devreoy identified 41 different definitions out of 47 studies conducted on poor ovarian 
responders. Furthermore, they found that not more than three trials used the same definition and the same 
authors used different definitions in different trials. (10). 
Parameters that have been used in defining poor ovarian responders include; peak oestrogen levels, number 
of dominant follicles on day of hCG (human Chorionic Gonadotropin) administration, number of oocytes 
retrieved, Day 3 Follicle Stimulating Hormone, Antiműllerian Hormone, Antral Follicle Count, previously 
cancelled IVF cycle due to poor ovarian response, total or daily gonadotropin dose, duration of gonadotropin 
administration and age ≥ 40 (7). 
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To introduce some consistency in the definition and to be able to compare results and make reliable 
conclusions from various studies on poor ovarian response, the European Society for Human Reproduction 
and Embryology (ESHRE) came up with a working definition, the Bologna criteria, for defining poor ovarian 
responder.  
In the Bologna criteria, at least two of the following three criteria are needed to define the poor ovarian 
responder: 
I. Advanced maternal age (≥40 years) or any other risk factor of poor ovarian response 
II. A previous ART cycle with poor ovarian response (cycle cancellation or aspiration with ≤3 
oocytes following conventional stimulation) 
III. An abnormal ovarian reserve test (AFC <5-7 follicles or AMH <0.5-1.1ng/ml) (7) 
A woman with a  history of two previous poor ovarian responses is also classified as a poor ovarian responder 
(7). 
Notwithstanding this monumental attempt to standardize the definition of poor ovarian response, there have 
been some criticism of the Bologna criteria. One of the main criticisms of the Bologna criteria is the lack of 
clearly defined risk factors for poor ovarian responders as used in the definition (29).  Some of the risk factors 
that have been suggested include ‘previous ovarian cystectomy for endometrioma, short menstrual cycle, 
single ovary, chemotherapy, radiotherapy, chronic smoking, family history of premature menopause, 
chromosome derangement, fragile X mental retardation premutation and unexplained infertility. Most of these 
factors have not however been validated’ (20). There is therefore a very high possibility of having various 
subgroups if these risk factors are used in identifying poor ovarian responders. 
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Papathanasious et al in their analysis of the different permutations of the three Bologna criteria derived four 
subgroups and up to eight subgroups if the combinations included the supplemental criteria of a history of 
two previous poor ovarian response. They opined that the different subgroups may have different outcomes 
(30). 
Several authors have recognized that young women with poor ovarian response have a better prognosis than 
older poor ovarian responders in terms of pregnancy outcomes(31, 32). In view of this fact, a group of fertility 
experts, the POSEIDON group, have proposed a classification system that stratify poor ovarian responders 
based on their age (<35 and ≥35) and ovarian reserve test. Four groups were identified (Group I –IV). Poor 
ovarian responders less than 35 years and a normal ovarian reserve test (group I) have a better pregnancy 
outcome than older women 35 and older with abnormal ovarian reserve test (group IV) (33). This classification 
system may be more predictive of clinical outcome and more useful in counselling patients regarding the 
expected outcome of IVF cycles.  
 Despite the limitations of the Bologna criteria, it is the first realistic effort to harmonize the definition of poor 
ovarian responders and its use has been recommended (34). 
1.4 OVARIAN RESERVE 
The response of the ovaries to gonadotropin stimulation is always a retrospective assessment and therefore 
can only be judged after the ovaries have been stimulated. It would however be ideal to accurately predict 
poor ovarian responders before initiating IVF treatment cycles. The purpose of ovarian reserve testing is to 
identify patients who are at risk of poor response to ovarian stimulation with gonadotropins (35). 
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Several tests have been used in clinical practice to try to predict the likelihood of ovarian response to 
gonadotropin stimulation. Some of these screening tests such as the clomiphene challenge test, 
gonadotropin stimulation test, the exogenous follicle stimulation hormone ovarian reserve test, are laborious 
and are not reliable, hence are not routinely use in clinical practice. The ovarian reserve tests commonly 
used in clinical practice include basal Follicle Stimulation Hormone, (FSH), Antral Follicle Count (AFC) and 
Antiműllerian Hormone (AMH) (14). 
An increase in serum levels of basal FSH occurs with ovarian aging and follicular depletion. There is no 
universally accepted cut-offs values for basal FSH to identify poor ovarian responders (36). Women with high 
basal serum FSH values of more than 25mIU/ml have been found to have a poorer ovarian response and 
pregnancy outcomes compared to those with serum FSH of 15mIU/ml (37). Though Follicle Stimulating 
Hormone (FSH) levels have been found to fluctuate inter and intra cycle with the consequent low reliability, 
the test is still commonly used in many fertility centres probably because it has been extensively studied and 
used for many years and that it is relatively easy to perform not requiring any significant sample preparations 
(35).   
The number of follicles measured by transvaginal ultrasound in the early follicular phase is termed the antral 
follicle count. The AFC correlates with the pool of primordial follicles in the ovaries and the number of eggs 
retrieved after ovarian stimulation with gonadotropins. AFC is therefore a good indicator of ovarian reserve 
(14). 
 AFC is traditionally done with 2D ultrasound. The newer 3D ultrasound has some advantages including 
reduced shorter scanning time and storage capabilities with post procedure analysis (38). The 3D 
imaging for AFC however, does not seem to offer any significant advantage regarding information on 
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AFC (39). The use of real time 2D ultrasound is therefore adequate for measurement of AFC in clinical 
practice.  
Notwithstanding the widespread use of AFC, some authors have raised concerns about the use of AFC 
as ovarian reserve assessment for ART. There is variation in the clinical definition as well as technical 
methodology used in counting the follicles, even though there have been some efforts at standardization 
of the measurement of antral follicles. Additionally, there is no evidence that the antral follicles seen on 
ultrasound are potentially healthy with competent oocytes(40). The main drawback in the use of the AFC 
to predict ovarian reserve is that it must be done during the early follicular phase of the menstrual cycle (41).  
AFC has been found to be comparable to antiműllerian hormone in predicting ovarian response to 
gonadotrophins(42).  
Antiműllerian hormone (AMH) is a glycoprotein produced by the granulosa cells of small pre-antral and antral 
follicles in the ovaries (35). AMH is age dependant with highest values around menarche and virtually 
undetectable during the menopausal years. La Marca and colleagues clearly show a unique feature of AMH 
that its serum levels in not cycle dependent (43). The test can therefore be carried out on any day of the 
menstrual cycle.  The main drawback of AMH is the lack of universal standardized assay and variability of 
results from different laboratories, hence an AMH value using a particular assay cannot be equated to 
another AMH result using another assay (35).  The test for AMH also requires a specific storage condition 
and is laborious and time consuming. There is however some progress towards automation of AMH testing 
with the aim of performing the test within a short time (44).  Though some reports indicated a large variability 
of AMH in the population as well as a significant intra and inter cycle variation (45, 46), AMH have been 
found to be an excellent predictor of ovarian response to ovarian stimulation and the potential for cycle 




 None of the ovarian reserve tests is hundred percent accurate in predicting ovarian reserve. However, AFC 
and AMH have been found to be most reliable for predicting ovarian response and are the two tests that are 
used in the Bologna criteria to define poor ovarian response (43, 49). Abdelazim et al found a positive 
correlation between pregnancy rates and the two ovarian reserve tests AMH and AFC. However, both AMH 
and AFC are generally not regarded as good predictors of pregnancy (50). In the prediction of ongoing 
pregnancy after IVF, Broer et al in their meta-analysis of individual patients data, found very small or no 
predictive effect. Their analysis indicates that FSH, AFC and AMH show AUC of 0.53, 050, and 0.55 
respectively indicating no added predictive effect to patient characteristics (17).  
 
1.5 PREVALENCE OF POOR OVARIAN RESPONSE 
The reported prevalence of poor ovarian response is widely variable. Prevalence rates of between 9 and 
26% have been reported(19). This wide variability is mainly due to lack of a standard definition as such 
various authors used various definitions for poor ovarian response. A more reliable prevalence could only be 
achieved with standardization of the definition of poor ovarian response. Recent studies show prevalence 
rates that seems to be higher than previous estimates. This apparent increasing prevalence of poor ovarian 
response is particularly evident with the introduction of the Bologna criteria. Devine et al, in the review of 
patients with diminished ovarian reserve in the Unites States Assisted Reproduction Technology (US ART) 
population, comparing 2004 and 2011 data, found that almost 70% of the patients that were allocated as 
poor responders on clinical basis, using the Bologna criteria, did not experience poor ovarian response after 
stimulation. This apparent increase in prevalence of poor ovarian response using the definition for the 
Bologna criteria seems to be due mainly to over-diagnosis on clinical grounds (22). 
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There have been conflicting reports on the influence of ethnicity and race on prevalence of poor ovarian 
response. Bhide et al found no independent association between AMH and ethnicity in unselected population 
of women undergoing ovarian stimulation for IVF (51). Lashen et al also found no difference in ovarian 
response to controlled ovarian stimulation between Asian women and white Caucasians (52). However 
Iglesias  have documented diminish ovarian reserve in Indians compared to the Spanish women (53).  In 
general, the prevalence of poor ovarian response does not seem to be influenced either by race or ethnicity. 
1.6 GONADOTROPIN DOSE 
In a natural cycle, a woman produces one dominant follicle containing an oocyte in her ovary per month. 
Gonadotropin medication can be administered to stimulate the ovaries to produce multiple dominant follicles, 
each follicle usually containing an oocyte. However, a minimum dose of gonadotropin is needed for 
recruitment and growth of these multiple follicles. The administration of insufficient dose of gonadotropin 
below the threshold needed for multiple follicular recruitment would therefore lead to poor ovarian response 
and the recruitment of few eggs(54). The dose of gonadotropin is therefore an important element during a 
controlled ovarian stimulation for IVF in a poor ovarian responder. 
In women who had previously experienced poor ovarian response, using higher doses of gonadotropin than 
previously used may result in improved outcomes, however a ceiling effect is likely to exist. Hofmann et al 
used a high FSH dose of 450IU in women who had previously responded poorly to FSH dose of 300IU. This 
led to reduced cycle cancellation and increased pregnancy rate(55). On the contrary, some authors found 
detrimental effect of the high and increasing doses of FSH on pregnancy outcomes.(56, 57)  Friedler et al, in 
their study of the effect of increasing doses of FSH, administered high dose (FSH 225IU -375IU), very high 
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dose (376- 450IU), or extremely high doses (451 -600IU) and found decreasing live birth rates with increasing 
FSH doses independent of age, BMI and previous cycle failure (56). This indicates that using very high doses 
of gonadotropin for ovarian stimulation may result in poor outcomes.  
Kailasam et al recommended the inclusion of dosage of gonadotropin used for ovarian stimulation in the 
definition of poor ovarian response. His suggestion was based on the finding that if higher total dose of FSH 
>3000IU was used during ovarian stimulation and the oocyte yield is low, the pregnancy outcome is poor and
the chances of retrieving higher number of eggs by increasing the gonadotropin dose in a subsequent cycle 
is low (58). This again shows the significance of gonadotropin dosage during ovarian stimulation in a poor 
ovarian responder.  
The optimum dose of gonadotropin for ovarian stimulation is not easy to estimate. Several nomograms and 
algorithms exist to help physicians choose the starting dose of gonadotropins (59-61). However, clinicians 
usually use a trial and error approach to determine the initial gonadotropin dose. 
 In a more recent multicentre trial, the OPTIMIST trial, which aimed to evaluate the effect of individualized 
versus standard dosing of gonadotropins in predicted poor ovarian responders undergoing ART, increasing 
the dose of gonadotropins beyond the standard dose of 150 IU does not result in increased live births but 
was associated with increased cost (62).  
In view of the conclusions of studies on gonadotropin dosage for controlled ovarian stimulation, using very 
high doses of gonadotropins with the aim of retrieving more oocytes and improving outcome of IVF in a poor 




1.7 CYCLE CANCELLATION 
The ground breaking event of the birth of the first baby through IVF resulted from the use of a single oocyte 
from a natural ovarian cycle (64). The discovery and introduction of ovarian stimulation with the resulting 
retrieval of several oocytes has increased pregnancy rates in ART (65). An adequate number of eggs is 
therefore an important determinant for improving the success in ART. 
A major reason for cycle cancellation is failure of the ovaries to respond adequately to the gonadotropin 
stimulation resulting in no follicular development or the development of normal size but too few follicles (66).  
Cycle cancellation could be classify into three based on when the cancellation occurs during the ART cycle.  
Cycles may be cancelled (i) during the ovarian stimulation due to poor ovarian response, (ii) after trigger but 
cancellation of embryo transfer if complications such as failure of fertilization (iii) cancellation of embryo 
transfer due to poor embryo quality or endometrial factors (67).   
The use of mild ovarian stimulation protocols, to either reduce the cost of IVF treatment and the risk of ovarian 
hyperstimulation is also associated with increased risk of cycle cancellation (68). This protocol is however 
not considered a standard stimulation protocol and therefore not sufficient to define poor ovarian response 
(7). 
A previous cycle cancellation due to poor ovarian response is associated with a higher risk of repeat cycle 
cancellation (69). It is however not definite that a previous cycle cancellation due to poor ovarian response 
would result in another cycle cancellation and in some cases the outcome may be favourable (70). On the 
other hand, it is almost definite that two consecutive previous cycle cancellations due to poor ovarian 
response will result in another poor ovarian response. This observation informed the decision to include two 
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previous cycle cancellations due to poor ovarian response as one of the definitions of poor ovarian response 
(7).   
The decision to cancel cycles due to poor ovarian response must be taken with regards to the age of the 
woman since young poor ovarian responders have higher pregnancy rates from their few available eggs than 
the older women with poor ovarian response (33). 
 
1.8 PREGNANCY OUTCOME IN POOR OVARIAN RESPONSE 
In general, poor ovarian responders have a lower pregnancy rate compared to normal ovarian responders 
though female age and number of eggs retrieved may significantly influenced the outcome (21). It has been 
postulated that the poor responders have lower pregnancy rates as a result of fewer oocytes which lead to 
few good quality embryos for transfer (71). The availability of good quality embryos for transfer is therefore 
an important determinant of the outcome of IVF in poor ovarian responders.  
Since the majority of women with poor ovarian response will not achieve pregnancy in the first IVF cycle, the 
low pregnancy rate must be discussed with the prospective couple early in the management of the poor 
ovarian responder.  Various models have been developed to predict the outcome of IVF cycles.  Of particular 
interest is the PROsPeR model which was designed specifically to predict the chances of live birth in the 
poor ovarian responder (72). The parameters used in formulating the PROsPeR model include age, number 
of oocytes retrieved in a previous cycle, AMH, AFC, type of infertility, cause of infertility, duration, previous 
number of pregnancies and previous number of ART. It was developed and validated using data gathered in 
a prospective study involving poor ovarian responders (73). The introduction of the PROsPeR model into 
clinical practice would help in counselling and managing expectation of patients with poor ovarian response.  
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In patients with poor ovarian response, younger women have better outcomes than women with advanced 
maternal age (21, 31). Despite a better prognosis in the younger poor ovarian responder, the pregnancy rate 
is lower than expected for a normal responder because of the few numbers of eggs and hence a few good 
quality embryos for transfer.  
 
1.9    COUPLES’ DECISIONS AFTER FIRST FAILED IVF 
The physical stress associated with the process of IVF can be enormous. Frequent hospital visits during the 
period for monitoring of follicular growth, the multiple gonadotropin injections and the retrieval of oocytes 
under anaesthesia are all physically demanding. Some women may not wish to undergo such physically 
exhausting process after a failed IVF cycle especially if the prognosis is presumed to be poor (74, 75).  
Assisted reproductive technology have been documented to be associated with psychological stress (74, 76). 
This is arguably more so in poor ovarian responders given the fact that the chances of pregnancy are slim. 
Interestingly, psychological interventions to reduce stress related to IVF treatment has not been shown to 
reduce drop-out rates, as such psychological counselling prior to initiation of  first IVF cycle may not be 
necessary (77). 
Financial stress is a common reason for discontinuation of treatment after a failed IVF especially in countries 
where IVF is funded out of pocket. This was evident in the study by Dyer and Vinoos who found that a quarter 
of couples who underwent IVF at a subsidized cost in the public health hospital in the Western Cape Province 
of South Africa could not recover financially four years after treatment for IVF procedure (78). 
It is important to manage the expectations of couples undergoing IVF particularly the poor ovarian responders 
due to their low success rate. Informing patients about the chances of success in the first IVF cycle and also 
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discussing the cumulative live birth rates in a number of treatment cycles may encourage some women and 
reduce disappointment and drop-out rates after the first IVF cycle (79). 
1.10 Summary of literature review 
Critical search and analysis of the literature shows a lack of standard definition for poor ovarian response 
and a wide variation in the prevalence and pregnancy rates in poor ovarian responders. The Bologna criteria 
was instituted as the first attempt to harmonize the definition of poor ovarian responder albeit the criticism of 
poorly defined risks factors of poor ovarian response and lack of definite end points of ovarian reserve tests 
used in the criteria. 
Compared with normal response, poor ovarian response is associated with higher risk of cycle cancellation, 
use of higher doses of FSH, retrieval of few eggs, few good quality embryos for transfer, poor IVF pregnancy 
rates as well as poor pregnancy outcomes.  
1.11 PROBLEM STATEMENT AND RESEARCH QUESTIONS 
There is evidence that poor ovarian response is associated with poor outcomes in IVF (21). The various 
choices that couples made after a failed IVF due to poor ovarian response have been documented (21, 27, 
79). 
 The infertile couple as well as fertility specialists need information in counselling, planning and deciding on 
the management of the couple with poor ovarian response. However, there is paucity of literature on poor 
ovarian response in the African setting.  Currently, the prevalence of poor ovarian response among women 
undergoing infertility treatment at the Reproductive Medicine Unit (RMU) of the Groote Schuur Hospital is not 
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known. Additionally, the outcomes of these cycles and the common choices that these couples made after a 
failed IVF cycle have not been documented. 
This study therefore seeks to answer the following questions among women with poor ovarian response 
undergoing assisted reproductive technology (ART) at Groote Schuur Hospital, 
• What is the prevalence of poor ovarian response in the study population? 
• What is the outcome following autologous IVF among the study population? 
• What choices do couples make after the first failed ART cycle? 
 
1.12  STUDY AIM AND OBJECTIVES 
AIM: To explore and document the frequency and treatment outcomes of autologous assisted reproductive 
technology in women with poor ovarian response undergoing infertility treatment at the Reproductive 
Medicine Unit of Groote Schuur Hospital.  
 
1.12  Primary objectives 
1. To determine the prevalence of poor ovarian response in women undergoing their first cycle of IVF/ICSI in 
the period of observation at the Reproductive Medicine Unit of Groote Schuur Hospital  
2. To determine the outcome of initiated cycles in terms of cycle cancellation, number of oocytes retrieved, 
pregnancy rates (biochemical, clinical and live birth) among women with poor ovarian response undergoing 





1.13  Secondary objectives 
To determine the treatment choices following first IVF/ICSI failure in women with poor ovarian response 



















This chapter describes the setting where the study was conducted, the study population, the process and 
procedure of ART at the Groote Schuur Hospital. It also details the method used in selecting the study 
subjects for this study as well as the data collection process and analysis. 
2.1  The setting and study population  
This study was conducted at the Groote Schuur Hospital, a level 3 referral centre in the public-academic 
health sector in the Western Cape Province of South Africa. The setting was the Reproductive Medicine Unit 
of the Groote Schuur Hospital, one of two Government and referral Hospitals which provide tertiary services 
for infertility treatment in the Western Cape Province. All infertility treatment options including ovulation 
induction, intrauterine insemination, in-vitro fertilization and ICSI are offered at the Unit. The Western Cape 
Government partially subsidises infertility treatment at the Groote Schuur Hospital. The hospital has a criteria 
that clients must meet to be eligible to enrol and benefit from the subsidy for the ART procedure. 
The study population comprised women who were referred for infertility treatment and who had undergone 
IVF/ICSI at the Reproductive Medicine Unit within a five-year period between 1st January 2011 and 31 






2.2 Type of study 
The study was a retrospective descriptive study. 
2.3 Inclusion criteria 
1. The Bologna criteria was used in selecting women for inclusion in the study. Women meeting any two of
the following three criteria were included in the study: 
I. Advanced maternal age (≥40 years) or any other risk of poor ovarian reserve
II. A previous ART cycle with poor ovarian response (cycle cancellation due to poor ovarian
response or aspiration of ≤3 oocytes) following conventional stimulation
III. An abnormal ovarian reserve test (AFC <7 follicles or AMH <1.1ng/ml)
2.4 Exclusion criteria 




The names, folder numbers and the cycle information of all women who underwent a standard ovarian 
stimulation for IVF/ICSI and who had any one of the following characteristics: 
➢ aged 40 or older,
➢ retrieval of ≤3 oocytes and
➢ cycle cancellation because of poor response
were retrieved from the existing electronic database of the Reproductive Medicine Unit of Groote Schuur 
Hospital.  
The folders of these patients were then retrieved and reviewed for the ovarian stimulation protocol that was 
used and the results of any ovarian reserve tests. Women who fulfilled two of the three eligibility criteria were 
selected for inclusion in the study. The folders of women selected to be part of the study were further reviewed 
for the data pertaining to the other study objectives (Appendix 1). The check list was developed based on 
literature regarding poor ovarian response. The data were entered on a spreadsheet. Each subject was given 
a study number to ensure patient anonymity and for easy data verification and for retrieval of uncaptured 
data.  
2.6 Data analysis 
Relevant data for this study were collected using a spreadsheet. The data were cleaned and exported to 
STATA version 14.0 (https://www.stata.com/) for analysis.  
Appropriate rates for background characteristics were presented. Measures of central tendencies, mean and 
standard deviation were calculated for BMI, duration of stimulation, total FSH dose and number of embryos 
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transferred. The mean was also computed for AMH, and AFC while percentages were computed for the 
number of cycles cancelled, clinical pregnancy and live birth rates and treatment options after failed IVF. 
 
2.7  Stimulating protocol 
The antagonist protocol was used for ovarian stimulation in all women undergoing assisted reproduction 
technology at the Groote Schuur hospital. All women were pretreated with combined oral contraceptives to 
enable batching of cycles.  
Ovarian stimulation was done with one of the following three follicle stimulation hormone medications; 
Menopur, (Ferring Pharmaceuticals, Switzerland) Gonal F (Merck Seronto, Germany), or Pergoveris (Merck 
Seronto, Germany). A dose of between 150 and 300IU of follicle stimulating hormone was injected daily for 
5 days. Ovarian response was assessed on day 6 of stimulation with transvaginal ultrasound and appropriate 
adjustments made to the FSH dose depending on the number of follicles and the size of the leading follicle. 
Serum levels of oestradiol, LH and progesterone were also checked. Daily doses of GnRH antagonist 
(Cetrotide, 0,25mg, Sherine, Switzerland) was started when the dominant follicular reached a size of 12mm 
or more. Follicular tracking with transvaginal ultrasound as well as serum oestradiol, LH and progesterone 
monitoring were done on alternate days from day 6 of stimulation till the day of ovulation trigger. 
 Ovulation trigger was done with human chorionic gonadotropin (hcg), (Ovitrelle, 10,000IU, Sherine, 
Switzerland) when at least 2 follicles were ≥18mm in size. In women with high risk of developing ovarian 
hyperstimulation, Lupron, 10-20ug, was used to trigger ovulation as an alternative to hCG. Each patient was 
given careful instructions regarding dosage, time of medication and method of administration. All medications 
were self-administered at home. Transvaginal ultrasound guided egg retrieval was done in theatre under 




2.8  Fertilization, embryo transfer, luteal support and pregnancy assessment 
All mature (metaphase II) oocytes retrieved were incubated with sperm about 3-5 hours after oocyte retrieval. 
In case of poor semen quality, ICSI was performed. Confirmation of fertilization by observing the presence 
of two pronuclei was done 16 to 18 hours after insemination. 
 The Gardner and Schoolman classification was used to grade the embryos. Embryo selection for transfer 
was done by one of the three embryologists. Blastocysts were transferred on day 5 while cleavage stage 
embryos were transferred on day 3 if there were few embryos or concerns that embryos may not survive to 
the blastocyst stage.  
 Embryo transfer was done, under ultrasound guidance, by one of the four sub-specialists or a fellow in 
Reproductive Medicine under the supervision of a sub-specialist consultant. It is the policy of the Groote 
Schuur Hospital that either one or a maximum of two embryos are transferred per patient per cycle.  
Vaginal progesterone (Utrogestan, Merck Soronto, Milan, Italy) 200mg twice a day, was used for Luteal 
support starting on day of egg retrieval until pregnancy test. Pregnancy test with quantitative serum β-hCG 
was done at the Groote Schuur hospital 10 days after a day 5 embryo transfer and 12 days after a day 3 
embryo transfer.  
Clinical pregnancy was assessed by observation of a gestational sac with or without fetal pole or cardiac 
activity by transvaginal ultrasound six weeks after embryo transfer.  
Women with clinical pregnancy were referred for antenatal care in a secondary level hospital. Pregnant 
women with high risk for pregnancy complications had tertiary level antenatal care at the Groote Schuur 





During the study period, 1120 IVF cycles were done.   Forty patients met the Bologna criteria for poor ovarian 
response. Fig 1 shows the flow chart for selection of patients who met the Bologna criteria and were included 
in the study. It also shows the outcome of initiated cycle. 
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3.1 BACKGROUND CHARACTERISTICS 
Table 1 Shows the background characteristics of the patients. The youngest was 25 years while the oldest 
was 42years and the median age was 40.0years. More than half (52.5%) of the patients were 40 years or 
older. Of those with available data, majority (60%) have BMI above normal. No patient had BMI of more than 
34kg/m2.  
Table 1: Baseline characteristics of study sample (n=40) 
Characteristics Distribution 















BMI categories. (n=25) 
Underweight (BMI < 18.5kg/m2) 
Normal weight (BMI: 18.5 -24.9kg/m2) 
Overweight (BM: 25-29.9kg/m2) 







3. 2  INDICATIONS FOR ART 
Fig 2 shows the distribution of indication for ART. The commonest indication for ART, among the poor ovarian 
responders, was advanced age of the female partner which accounted for 35.0% of the IVF cycles.  











3.3  OVARIAN RESERVE TEST 
A total of thirty-three (82.5%) patients had an ovarian reserve test done.  Twenty-seven (67.5%) of patients 
had AMH done. The median AMH was 0.37ng/ml.  


























3.4  DURATION OF STIMULATION AND CYCLE CANCELLATION 
 Table 2 shows the duration of stimulation, total amount of FSH used and the number of cycles cancelled. 
The median duration of stimulation was 9.0 days while the average total amount of FSH dose used in those 
who underwent egg retrieval was 2987.8 IU 
Six (15.0%) cycles were cancelled prior to ovum pick up due to poor ovarian response. The average number 
of eggs retrieved was 1.8.  












Duration of stimulation, median 
 
9.0  days 
Total amount of FSH used, mean (SD) 2987.8 (306.4) IU 
 






3.5 EMBRYO TRANSFER 
Twenty-four patients (60%) underwent fresh transfer after retrieval. The Number of embryos transferred are 
shown in table 3 
Table 3: Number of embryos transferred  
Number of Embryos Transferred N 
Single embryo transfer  13 
Double embryo transfer  11 
 
 
Table 4: OUTCOME PER INITIATED CYCLE 
 Pregnant, n=8 (20%) 
Biochemical pregnancy 
Clinical pregnancy  













3.7: DECISION AND TREATMENT OPTIONS AFTER FAILED IVF 
 Fig 3 shows the decision and treatment options adopted by women with poor ovarian response after their 
first failed IVF cycle. Half of the couples withdrew from the program 





Decision after first failed IVF 
Accept childlessness
Donor cycle






This chapter discusses the study findings with reference to previous studies on poor ovarian responders. 
Possible reasons were ascribed, where appropriate, for some of the discrepancy between the findings of this 
study and previous studies.   
The results of this study show that the median age and BMI were 40years and 27.0kg/m2 respectively. Six 
cycles (15.0%) were cancelled prior to egg retrieval while the average number of eggs per aspiration was 
1.8. Twenty-four women had at least one embryo transferred. Of the 40 initiated cycles, eight (20.0 %) 
resulted in a positive pregnancy test.  Of these, four were clinical pregnancies (10.0%) resulting in two live 
births (5.0%) per cycle initiated. Among the women who did not achieve live birth, half withdrew from further 
ART cycle. 
 
4.1  PREVALENCE OF POOR OVARIAN RESPONSE  
The prevalence of poor ovarian response in this study was 3.6%. This is much lower than previous studies 
that estimated the prevalence of poor ovarian response to be between 9 and 24% (19). The low prevalence 
rate in this study may be due to the high number of cases where ovarian reserve tests were not available. 
Absence of ovarian reserve test could exclude two groups of participants that may have been included in 
the study: Firstly, women <40 years with ≤ three oocytes in whom ovarian reserve tests were not available; 
and, secondly women ≥40 years with > three oocytes in whom ovarian reserve tests were not available. 
Additionally, the definition of “risk factors for poor ovarian response” as one of the criteria for poor ovarian 
response in the Bologna criteria have not been clearly defined (29). Various authors used these poorly 
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defined risk factors to variable extent in their studies  which may affect the prevalence rate (20). There was 
no use of any of these poorly defined risk factors for inclusion into the study. The exclusion of these patients 
who may have one or more of these risk factors which were not specifically captured in the ART database 
or the medical records may have contributed to the low prevalence.  
Another factor that may have influenced the low prevalence is the criteria for inclusion into ART program at 
the Groote Schuur Hospital. The reproductive medicine unit has a policy to offer autologous ART up to 43 
years because of the low probability of pregnancy in women >43years and the fact that treatment costs are 
in part funded through government resources. The exclusion of older women from autologous ART may 
contribute to the relatively low prevalence of poor ovarian responders found in this study.  
 
4.2  AGE 
Advanced female age with infertility is one of the indications for ART. The chronological age of a woman is 
an important parameter that is associated with ovarian ageing and poor ovarian response both of which 
influence success in ART(80-82). The median age of patients in this study was 40.0 years. The oldest patient 
was 42 years. Additionally, more than half of the women in the cohort were 40 years and older. The finding 
of large proportion of advanced female age in this study is similar to other studies where there is high 
proportion of advanced maternal age among poor ovarian responders defined using the Bologna criteria  
(83, 84). The skewed distribution of advanced maternal age among the poor ovarian responders in the study 





 4.3  OVARIAN RESERVE TEST 
The median for AFC in the study group was five. This is comparable to the average AFC found in other 
studies among poor ovarian responders (83).  It was noted that only 15% of women had AFC documented, 
despite it being a reliable, non-invasive and accurate estimation of ovarian reserve test.  Doing AFC alone 
has been found to be the most cost effective assessment for predicting the ovarian response in patients 
undergoing IVF (85).    
Antral Follicle Count needs to be done within the early follicular phase of the menstrual cycle. Some of the 
patients may not be able to return within the time frame and therefore the AFC is forfeited.  Compared to 
AFC, AMH as an ovarian reserve test can be done on any day of the menstrual cycle. 
The mean AMH value in the study population was 0.37ng/ml suggesting that few eggs are likely to be 
retrieved with standard ovarian stimulation.  AMH reduces with advancing age, reflecting diminishing ovarian 
response (86). More than half of the women in the study population were more than 40 years hence the 
median AMH is expected to be low.  
The proportion of patients with available AMH results (67.5%) was not as high as expected given the high 
proportion of women with advanced maternal age in the study population. Some of the reason for not doing 
AMH in all patients prior to ART procedure may be four-fold. Firstly, while some fertility centres use AMH to 
disqualify women from undergoing IVF based purely on the chance of anticipated low response, other 
hospitals including the Groote Schuur hospital, do not use AMH in disqualifying women from inclusion in 
IVF programs because patients with very low AMH can still achieve pregnancy through IVF(87). It may 
therefore not be necessary to check AMH levels in all individuals before commencing ART. It is however a 
useful tool in counselling patients on the possible number of eggs that could be retrieved. Secondly, ovarian 
stimulation with gonadotropins is a dynamic test for ovarian response and none of the ovarian response 
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tests is full proof hence a strategy of entering the first cycle of IVF without any prior ovarian reserve test 
have been proposed (66). Some reproductive specialists do not routinely do AMH prior to ovarian stimulation 
but use the outcome of the stimulation to test the response of the ovaries to gonadotropin stimulation. 
Thirdly, AMH would give an indication of the number of eggs but does not predict the chances of pregnancy 
(88). Additionally, AMH is expensive and hence may not be cost effective to routinely do prior to ovarian 
stimulation.  
4.4 GONADOTROPIN DOSE AND DURATION OF STIMULATION 
The average total amount of gonadotropins used for ovarian stimulation of the women in the study was 2987.8 
IU. This is low compared to other studies where a total FSH dose used in poor ovarian responders were 
much higher. Sandeen et at, Busnelli et al and Merviel et al, found an average total FSH dose of 4135IU, 
3600IU, 4664IU respectively among poor ovarian responders stimulated for IVF (81, 89, 90). One of the 
factors that determines the total FSH dose is the duration of stimulation. An average number of days of 
stimulation in the study population was 9.5 days which was shorter than that found in other studies in 
Bologna poor responders (89).  
One of the reasons for the short duration of stimulations may be asynchronous follicular growth during ovarian 
stimulation. This phenomenon is more common when antagonist protocol was used. If this occurs in poor 
ovarian responders, when 2 or 3 leading follicles are of adequate size, but the rest are too small to anticipate 
any mature oocyte, trigger is given, and the dominant follicles aspirated shortening the whole duration of 
stimulation. However, a comparison with the average duration of stimulation of normal responders at the 
Groote Schuur Hospital would give a clearer perspective if there is any significant difference in the duration 
of stimulation in the poor responder group.  
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4.5  CYCLE CANCELLATION 
Central to the success of IVF procedure is the retrieval of an adequate number of oocytes. In cases of poor 
ovarian response where there are too few follicles, cycle cancellation is a recognized management 
option(69). The cycle cancelation rate in this study due to poor ovarian response was 15.0%. This finding 
shows a higher cycle cancellation rates compared to a study in Milan, Italy where the cycle cancellation rate 
among poor ovarian responders was 6% (89). The high proportion of women with advanced maternal age 
in the study population may have also contributed to the high cycle cancellation rate.  
This cycle cancellation rate is however much lower than another study in Barcelona, Spain where the cycle 
cancellation rate was 54.2%. Their higher cancellation rate may be because their cohort of poor responders 
had a previous cycle cancellation due to poor response which make this cohort more likely to experience 
another poor ovarian response (69). 
The women whose cycles were cancelled due to poor ovarian response may have to undergo another IVF 
cycle. This is likely to be associated with great anxiety as there is the likelihood of similar experience of poor 
response in the subsequent cycle. 
 4.6 NUMBER OF EGGS RETRIEVED, NUMBER OF EMBRYOS TRANFERED 
The retrieval of an adequate number of eggs increases the chance of having a good embryo to transfer. 
The mean number of eggs retrieved in this study was 1.8. This finding is similar to other studies where the 
average number of eggs retrieved in Bologna poor ovarian responders were few (83, 84). 
The selection and transfer of a single good quality embryo is being advocated as the standard in ART. The 
aim of the single embryo transfer is to reduce multiple pregnancy and its associated complications while 
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making efficient use of all oocytes retrieved in one cycle(91, 92). In cases of elective single embryo transfer, 
there is usually several good quality embryos from which one embryo is selected. However, in the case of 
poor ovarian responders, there is usually very limited options due to the very few embryos available.  
4.7 OUTCOME OF INITIATED CYCLES /PREGNANCY SUCCESS 
A live birth is the desire of every patient undergoing fertility treatment. The live birth rate in the study 
population was 5.0% per initiated cycle. This is comparable to live birth rates of 4-7% found in Bologna poor 
responders in recent studies (22, 89, 93). While this low chance of live birth may be acceptable to some 
women with poor ovarian response undergoing ART, others may find it unacceptably low and may not wish 
to embark on this expensive and psychologically stressful process of ART. The Ethics Committee of the 
American Society of Reproductive Medicine opined that if the chance of live birth following IVF procedure is 
nonexistence or up to 1%, the procedure is said to be futile and is probably not worth performing. Expected 
outcomes of between 1% and 5% chance of success are said to be very poor and other appropriate options 
may be offered. In instances of futile or very poor prognosis, the decision to proceed with the procedure 
rests with the patient once the clinician has informed the patient of low odds of success (94).  
The pregnancy rate in ART is greatly influenced by the quality and number of embryos. In situations where 
there are few embryos to select from, the pregnancy outcome is poor. Ovarian response and the number of 
available eggs also depend largely on the age of the woman. There was a high proportion of women with 
advanced age and there were few available embryos for transfer. These two factors may have contributed 
to the low pregnancy rate in the study population. 
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The age of a woman may significantly alter the outcome of ART in poor responders.  It is important to note 
that the study population was not stratified by age. Stratification by age would have helped to target our 
counselling to the age specific rates which may relate more to patient’s peculiar situation. 
 
4.8  DECISION AFTER FIRST FAILED IVF CYCLE 
Withdrawal from the ART program was the commonest choice (50.0%) for women in the study population. 
This rate was high compared to a study in Netherlands where 17% drop-out rate was found.(95) The co-
payment method of financing ART  at the Groote Schuur hospital may explain the high dropout rate as the 
financial recovery rate after IVF is very slow among most couples in the Western Cape Province of South 
Africa (78). These patients who withdrew or drop out from the program include those who deliberately decide 
not to undergo further treatment and patients who failed to return for follow-up and were not or could not be 
contacted. Some of these patients in the latter group may have gone to other fertility centres for further 
management.  
Maternal age is one of the factors considered to be associated with dropout rates(79). The study population 
has a high proportion of advanced maternal age with more than half of the study subjects older than 40years. 
This may be another reason for the high dropout rate.  
Male factor is a common indication for ART.  Male factor infertility was the third most common indication for 
initiating ART in the study population. It forms 20% of the indications for the ART. It has been documented 
that males are more likely not to want to continue ART program after a failed IVF(96). The high proportion 
of male factor infertility in the study may have also contributed to the high discontinuation rate observed in 
the study.  
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Couples who have embryos frozen for future use are also more likely to continue the program than couples 
who do not have embryos frozen when their cycle failed (79).  The glimpse of hope of pregnancy from the 
available embryos without the stress of going through another stimulation cycle is non-existent for these 
couples without frozen embryos. The absence of frozen embryos for future use by women in the study 
population might have contributed to the high withdrawal rate found in the study. 
Five percent of women accepted childlessness after the first failed IVF and follow up counselling. This is 
usually a difficult decision for patients because of the social implications of childlessness in Africa (2). 
4.9 LIMITATIONS 
The retrospective nature of the study depends on adequacy of collected data. Some information relevant to 
this study may not be available in the electronic database or in the patients’ folder. These missing data may 




In relation to the primary study objectives, the prevalence of poor ovarian response, (3.6%) in patients 
undergoing ART at Groote Schuur Hospital is low. The outcome of initiated cycle reveals that there was 
high cycle cancellation rate and few eggs were retrieved. The clinical pregnancy and live birth rates were 
low in this cohort of poor ovarian responders.  
In relation to the secondary objectives, it was found that there was a high dropout rate after the first failed 
IVF among the poor ovarian responders. Although financial recovery after IVF has been documented to be 
very slow in patients undergoing ART at the Groote Schuur  hospital, follow up studies on the reasons for 
the high dropout rate among the poor responders would be essential for planning a strategy to assist patients 
make other choices in fulfilling their desire to have children as well as counselling and support if they decide 
to accept childlessness. 
The results of the study will be of value in providing potential patients with specific information regarding 
outcome of ART in poor ovarian responders. It would also aid counselling regarding expectations among 
poor ovarian responders in the Western Cape Province of South Africa. 
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Data collection sheet 
A. SOCIODERMOGRAPHIC CHARACTERISTICS 
I. Age (years)  a.< 40         b. ≥40    
56 
2. Employment status a. Employed b. Unemployed
3. Marital status a. Married b. Single c. Separated d. Divorced e. Cohabiting
4. BMI   a. <18.5    b. 18.5-24.9    c.25-29.5   d. 30-34.9    e. >35
6. Duration of infertility
7. Indication for ART a. Tubal factor   b. Male factor c. Endometriosis d. Unexplained e. Advanced maternal
age 
B. Ovarian Response Test
8. AMH:     result
9. AFC:     result:
C. Ovarian response
10. Cycle cancellation   1.yes    2. No
11. Number of oocytes retrieved.
12. Duration of Stimulation (In Days):
13. Total amount of FSH used:
D. Fertilization
14. Method of Fertilization: 1. IVF     2. ICSI









18. Treatment after first cycle I. Repeat ART cycle with self-cycle
II. Donor cycle
III withdrew from program 
IV. accept childlessness
APPENDIX 2: ETHICS APPROVAL 
58 
Signature Removed
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